Zota Health Care Acquires 39,228 Shares in Wholly Owned Subsidiary Davaindia
Zota Health Care acquired 39,228 equity shares in its wholly owned subsidiary, Davaindia Health Mart Limited, for ₹19.91 crore. This strategic investment aims to support the subsidiary's working capital. Davaindia Health Mart reported a turnover of ₹267.71 crore in FY26.
The acquisition is a strategic investment in a wholly owned subsidiary that is showing significant revenue growth. While it is a substantial amount, it is an internal fund movement within the group and does not immediately indicate a significant external market impact.
The company has made a strategic investment in its subsidiary, which is a routine business activity. While it supports working capital, there are no immediate significant financial gains or losses explicitly stated that would swing the sentiment strongly positive or negative.
Zota Health Care Limited has acquired an additional 39,228 equity shares in its wholly owned subsidiary, Davaindia Health Mart Limited, through a rights issue subscription. This strategic investment aims to support the working capital requirements of Davaindia Health Mart Limited.
Davaindia Health Mart Limited operates a retail generic pharmacy chain under the Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy. As of the financial year 2025-26, the subsidiary reported a turnover of ₹267.71 crore. The total paid-up share capital currently stands at ₹298.13 lakhs. The acquisition involved a cash consideration of ₹19,90,82,100.00, with each equity share acquired at ₹5075.00 (including a premium of ₹5065.00).
Davaindia Health Mart Limited, incorporated on January 01, 2020, operates 1855 COCO stores across 23 states and 5 Union Territories, offering over 2000 SKUs. The subsidiary's turnover has shown significant growth, from ₹44.77 crore in FY 2023-24 to ₹109.93 crore in FY 2024-25, and ₹267.71 crore in FY 2025-26. The company confirmed that this acquisition does not fall under related party transactions and is conducted on an arm's length basis.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.